Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. - Wikidata - awgldk - TriplyDB

Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial.

Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial.

http://www.wikidata.org/entity/Q35051753

about

Ticagrelor: molecular discovery to clinical evidence: ticagrelor: a novel antiplatelet agent Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial.Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety.Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapy.Critical appraisal of ticagrelor in the management of acute coronary syndrome Ticagrelor versus clopidogrel in real-world patients with ST elevation myocardial infarction: 1-year results by propensity score analysis Advances in antiplatelet technologies to improve cardiovascular disease morbidity and mortality: a review of ticagrelor Incidence, Time Trends, and Predictors of Intracranial Hemorrhage During Long-Term Follow-up After Acute Myocardial Infarction Almanac 2011: Acute Coronary Syndromes. The National Society Journals Present Selected Research that has Driven Recent Advances in Clinical Cardiology.Outcomes According to Cardiac Catheterization Referral and Clopidogrel Use Among Medicare Patients With Non-ST-Segment Elevation Myocardial Infarction Discharged Without In-hospital Revascularization Evaluating the risk-benefit profile of the direct-acting P2Y(12) inhibitor ticagrelor in acute coronary syndromes.Antiplatelet therapy in acute coronary syndromes.P2Y12 platelet inhibition in clinical practice.A comprehensive comparative review of adenosine diphosphate receptor antagonists.Emerging antiplatelet therapy for coronary artery disease and acute coronary syndrome.Antithrombotic therapy in patients with acute coronary syndrome and diabetes mellitus.Which antiplatelet agent for whom? Which patient populations benefit most from novel antiplatelet agents (ticagrelor, prasugrel)?Comparative pharmacokinetics and pharmacodynamics of platelet adenosine diphosphate receptor antagonists and their clinical implications.Platelet adenosine diphosphate receptor antagonists: ticlopidine to ticagrelor-a long continuing journey.Ticagrelor: a P2Y12 antagonist for use in acute coronary syndromes.Safety profile and bleeding risk of ticagrelor compared with clopidogrel.P2Y12 receptor: platelet thrombus formation and medical interventions.The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day.The challenge of antiplatelet therapy in patients with atrial fibrillation and heart failure.Ticagrelor: the first novel reversible P2Y(12) inhibitor.Cost-effectiveness of ticagrelor in acute coronary syndromes.Antiplatelet therapy: new pharmacological agents and changing paradigms.Clopidogrel, prasugrel, or ticagrelor? a practical guide to use of antiplatelet agents in patients with acute coronary syndromes.Assessing post-treatment platelet reactivity: a focus on patient selection and setting.Use of antiplatelet agents in patients with atherosclerotic disease.Ticagrelor for acute coronary syndromes.Updates in antiplatelet agents used in cardiovascular diseases.New antithrombotics for secondary prevention of acute coronary syndrome.Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI.Management of acute coronary syndrome in the hospital: a focus on ACCF/AHA guideline updates to oral antiplatelet therapy.Novel antiplatelet agents in acute coronary syndrome.Contemporary antithrombotic strategies in patients with acute coronary syndromes managed without revascularization: insights from the EYESHOT study.The future of P2Y12 receptor antagonists.Clopidogrel Response Variability: Review of the Literature and Practical Considerations.Clinical pathways and management of antithrombotic therapy in patients with acute coronary syndrome (ACS): a Consensus Document from the Italian Association of Hospital Cardiologists (ANMCO), Italian Society of Cardiology (SIC), Italian Society of E

P2860

Q26829967-3696B821-EF91-4A87-B906-33AEA39E5816 Q34043989-722B0627-6558-4042-8B3C-464DE297797C Q34805121-54E15032-BED6-4407-B521-30127958BF10 Q35048557-4015A1BA-FB92-4584-918F-4B5040C4A661 Q35660767-9633EDDB-0A32-4210-8EAF-B9BFFF27BC7A Q36337254-54F823E4-9841-4DF4-975D-4FA5F74D2CA8 Q36807413-3EFBAC6C-332A-4012-9806-23F63F794599 Q36836368-C3DC1B51-6E29-4172-94AC-1AB1131D647C Q37066826-9E049486-F589-413C-A49C-2CF0701B7DF2 Q37090758-557C058D-3428-44E4-9A73-C6BC5C393B25 Q37959155-A3ED57F1-247A-4708-B00B-66E8D61905FF Q37965609-56BE49A2-58A8-4C0D-B5D5-2D46F65038D5 Q37969927-8FF02AD3-BC06-4C2C-A145-90DE2DE04850 Q37973114-8C0DF9B4-1DBA-4A19-82E9-9294984F4FB8 Q37990848-013180F0-B9AC-4985-B6ED-C64BE223BB54 Q37997963-A2F4C666-8041-4B93-9B77-62FDC8F6C436 Q38005621-98969C73-A745-4D35-834B-2E7C0A1346BA Q38008466-946D77DF-2899-4FF4-9B41-F19117792915 Q38008828-8CA55F40-8E4E-42B7-BB44-5BBC0240E901 Q38018674-5410703C-1F87-429F-A50A-3D7EA3524F91 Q38040816-0CE0B2FD-75EB-4BB5-BD7E-6C7F7F003AF9 Q38051192-A01211DC-701C-4E54-9A47-C31268ED7A30 Q38053481-AC47243B-EB41-4107-88FA-2A9DA34CDCC5 Q38064758-7572998D-23F1-403F-9916-E1F78AADBED5 Q38069896-F13C140A-4170-4695-AC31-614A724B79DD Q38080910-60A297D2-9FEC-4683-A27E-20493372759B Q38117743-2D4FBAC5-A8F3-40DE-AD7A-536475D34BBB Q38128171-59C6E1D5-D408-4EC9-96DE-BA91204C084E Q38132923-4625AE0F-AAF8-40F8-B987-E1AC1654209C Q38151446-E616E938-0AE0-4B10-8A0B-0DF753856ED7 Q38154611-633F2C2F-9FE2-484C-B421-5A62EBA68A1A Q38161394-1FA3C94A-0EED-4B8C-88BF-60A277F7906D Q38180991-CA7E8832-3A62-4D8C-8151-31529A23FB4F Q38243032-17F38E94-3EC2-4B77-B2F7-A513EFBCE042 Q38254245-18FF0556-8940-45D9-8853-BBFE8A142CC0 Q38257119-1B374BCE-D86F-4BB9-9FAD-4999D983D378 Q38388751-9E5F5F41-D86F-4E04-8DA0-5795EF99F492 Q38515684-BBE57337-0119-4AF7-BA37-C9D95A430459 Q38640902-E1FF470B-358B-4B51-B3DE-83314AE2C8C5 Q38656364-12C9E52A-B818-4057-A2D9-351997B11685

P2860

Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial.

http://www.wikidata.org/entity/Q35051753

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Ticagrelor versus clopidogrel ...... atient Outcomes (PLATO) trial.

@ast

Ticagrelor versus clopidogrel ...... atient Outcomes (PLATO) trial.

@en

type

label

Ticagrelor versus clopidogrel ...... atient Outcomes (PLATO) trial.

@ast

Ticagrelor versus clopidogrel ...... atient Outcomes (PLATO) trial.

@en

prefLabel

Ticagrelor versus clopidogrel ...... atient Outcomes (PLATO) trial.

@ast

Ticagrelor versus clopidogrel ...... atient Outcomes (PLATO) trial.

@en

P1433

Q35051753-4692644B-161C-4839-AAE4-9646007EFC8B

P1476

Q35051753-0765CE7F-1010-4EBF-86A9-E0BEE91650CF

P2093

Q35051753-28F6A8F6-2B23-47AD-8EB3-FA5D726AA57E

Q35051753-2D893393-B375-4693-AEBB-22DDA66C57E7

Q35051753-66EC8DF7-CCD3-4B36-9BB3-4E9CECF7FCDD

Q35051753-A517DCF9-2056-4880-8151-52F04F348A11

Q35051753-B52B7F4F-BCCB-4E25-A69F-28B1B91BCAD1

Q35051753-BD4BDDA7-1B82-46CB-B7F0-7AE654724667

Q35051753-C4B487D7-6652-4C7E-975E-B539B3ABC86E

Q35051753-E2A873A1-A7EB-40E6-9314-2F8CDC8F7356

Q35051753-FA61EB15-8C6C-4975-815D-2F74C7D6E0F7

P2860

Q35051753-290053A2-4E95-4634-A59D-E71EE01138E6

Q35051753-453E775D-A95A-4F0E-B6EB-B3518BC61C0D

Q35051753-7D7EF51A-C81E-4088-834F-D36282CD5CD5

Q35051753-827D3571-B0B8-4EDB-AEAB-FA711EB7EAAF

Q35051753-898B4728-0408-4DEB-A7FD-FF2793271C98

Q35051753-8C1EC1AB-0DC7-4E3F-8155-F28754ED31DA

Q35051753-95FB4C37-92B6-4836-9F5A-1F5A23767466

Q35051753-A8F7B1EC-7473-40D4-9093-59B5DBC5A3AF

Q35051753-B253CBF5-A938-4779-9A18-CC76D46090FD

Q35051753-BADF149F-EA16-4B9C-BFF8-97F9E2EC1360

P304

Q35051753-1E60DE1C-CDEF-4AC9-A87B-45D35070FECA

P31

Q35051753-38BD92F6-34B2-431D-A41F-639600AF1141

P356

Q35051753-D235014F-CA51-403A-AA88-D92BBE36CCA1

P407

Q35051753-92C11763-6AB7-4909-A4CE-4D787084CF51

P478

Q35051753-5E216CD6-7FF0-4DFE-9F7B-714BED602D52

P50

Q35051753-03677D11-E1FC-4119-A3A4-FE21C9A09D7C

Q35051753-2A4C8969-39FA-419D-B3B1-56B480169A59

Q35051753-6D23F47D-A962-4909-88DF-547CC79693AF

Q35051753-7FB7A8C3-A11E-4CCE-8DFD-7833EF16320E

Q35051753-F2BF8190-3742-45A9-A27B-B493D66337D6

P577

Q35051753-D08A00CA-E8A2-41E0-8C2E-65E8797AD568

P5875

Q35051753-505E7467-01AB-4C5D-8B11-A35FC8DB5CD5

P698

Q35051753-1D6E8509-957D-4FD0-94EE-EA68913E6500

P921

Q35051753-304C82A0-263A-4FF3-B1C2-85B81CAEA48D

Q35051753-44DE2F39-40BD-4421-9E9B-C4A0E5862F0A

P932

Q35051753-35CF8B0B-CF9B-40AB-A307-7454CEB3A4E6

P356

P1433

P1476

Ticagrelor versus clopidogrel ...... atient Outcomes (PLATO) trial.

@en

P2093

Christopher P Cannon

http://www.w3.org/2001/XMLSchema#string

Hugo Katus

http://www.w3.org/2001/XMLSchema#string

Jan H Cornel

http://www.w3.org/2001/XMLSchema#string

Jay Horrow

http://www.w3.org/2001/XMLSchema#string

PLATO Study Group

http://www.w3.org/2001/XMLSchema#string

Ph Gabriel Steg

http://www.w3.org/2001/XMLSchema#string

Steen Husted

http://www.w3.org/2001/XMLSchema#string

Stefan K James

http://www.w3.org/2001/XMLSchema#string

Susanna Stevens

http://www.w3.org/2001/XMLSchema#string

P2860

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study

Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial

Early invasive versus selectively invasive management for acute coronary syndromes

Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups

Early and late effects of clopidogrel in patients with acute coronary syndromes

Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study.

ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Rev

Noninvasive, medical management for non-ST-elevation acute coronary syndromes.

P304

d3527

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/BMJ.D3527

http://www.w3.org/2001/XMLSchema#string

P407

P478

342

http://www.w3.org/2001/XMLSchema#string

P50

Robert F. Storey

Robert A Harrington

P577

2011-06-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51230900

http://www.w3.org/2001/XMLSchema#string

P698

21685437

http://www.w3.org/2001/XMLSchema#string

P921

P932

3117310

http://www.w3.org/2001/XMLSchema#string